{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-020927","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.770174+00:00","generated_at":"2026-06-14T02:50:59.846653+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Cocrystal Pharma stockholders elect six directors, ratify auditor at 2023 annual meeting","bullets":["All six director nominees elected: Kornberg, Frost, Hassan, Japour, Pfenniger Jr., Rubin; votes ranged from 3.8M to 4.5M for.","Ratification of Weinberg & Company as independent auditor for FY 2023: 6,594,971 for, 186,279 against.","Non-binding advisory vote on named executive officer compensation approved: 3,668,840 for, 976,339 against.","Proposal 4 (adjournment) declared moot due to sufficient votes on prior proposals."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-020927","json":"https://secwatch.observer/filing/0001493152-23-020927.json","markdown":"https://secwatch.observer/filing/0001493152-23-020927.md","text":"https://secwatch.observer/filing/0001493152-23-020927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223020927/0001493152-23-020927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223020927/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:50:59.846653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77dff54bfc2cf51a51c796f14671f116df624cea","claim":"Cocrystal Pharma, Inc. shareholders approved Ratification of the appointment of Weinberg & Company as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-08 meeting.","evidence_excerpt":"Proposal 2 . The Company’s stockholders voted to ratify the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 6,594,971 186,279 32,863","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223020927/0001493152-23-020927-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"b9ee4f2907e7515292987873f6b4f0fb3ed1ef69","claim":"Cocrystal Pharma, Inc. shareholders approved Election of six members of the Board of Directors for a one-year term expiring at the next annual meeting of stockholders at the 2023-06-08 meeting.","evidence_excerpt":"On June 8, 2023, the 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) of Cocrystal Pharma, Inc. (the “Company”) was held. At the 2023 Annual Meeting, the Company’s stockholders voted on (i) the election of six members of the Company’s Board of Directors for a one-year term expiring at the next annual meeting of stockholders (Proposal 1); (ii) ratification of the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (Proposal 2); (iii) approval of a non-binding advisory basis for compensation of the Company’s named executive officers (Proposal 3); and (iv) approval of an adjournment of the 2023 Annual Meeting to a later date or time, if necessary, to permit further solicitation and vote of proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the proposals presented for a vote at the 2023 Annual Meeting, all as described in more detail in the Com","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223020927/0001493152-23-020927-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"d4ccae70eef50e41e1163dacd6746a5c35602c5a","claim":"Cocrystal Pharma, Inc. shareholders approved Non-binding advisory approval of compensation of the Company's named executive officers at the 2023-06-08 meeting.","evidence_excerpt":"Proposal 3 . The Company’s stockholders voted to approve a non-binding advisory basis for compensation of the Company’s named executive officers. Votes For Votes Against Abstentions 3,668,840 976,339 58,387","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223020927/0001493152-23-020927-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}